Login to Your Account

Actelion Misses Endpoint In Chronic Heart Failure Study

By Kim Coghill

Friday, February 8, 2002
The failure of Tracleer to meet primary endpoints in a Phase III trial of chronic heart failure patients could be a blessing in disguise for Switzerland-based Actelion Ltd. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription